慢性炎性脱髓鞘性多发性神经病市场在预测期（2026-2036年）因临床研究活动的推进而获得增长动力 DelveInsight-动脉网

Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities

PR Newswire 等信源发布 2026-06-18 22:01



可切换为仅中文







The growth of the chronic inflammatory demyelinating polyneuropathy market is expected to be primarily driven by an expanding diagnosed patient population, improved disease awareness and diagnostic rates, increasing treatment uptake of immunoglobulin and targeted biologics, and the anticipated introduction of novel mechanism-based therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), Empasiprubart (argenx), NVG-2089 (Nuvig Therapeutics), DNTH103 (Dianthus Therapeutics), TAK-881 and TAK-411 (Takeda), and others..

慢性炎性脱髓鞘性多发性神经病市场的增长预计将主要由以下因素驱动：确诊患者群体不断扩大、疾病认知度和诊断率提高、免疫球蛋白及靶向生物制剂的治疗使用率上升，以及基于新机制的疗法（如赛诺菲的Riliprubart、Immunovant的Batoclimab、argenx的Empasiprubart、Nuvig Therapeutics的NVG-2089、Dianthus Therapeutics的DNTH103、武田制药的TAK-881和TAK-411等）的预期上市。

LAS VEGAS

拉斯维加斯

，

June 18, 2026

2026年6月18日

/PRNewswire/ -- Recently published Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. .

/PRNewswire/ -- 最近发布的《慢性炎性脱髓鞘性多发性神经病市场洞察》报告包括对当前治疗实践、慢性炎性脱髓鞘性多发性神经病新兴药物、各疗法的市场份额以及2022年至2036年当前和预测市场规模的全面理解，按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行细分。

Chronic Inflammatory Demyelinating Polyneuropathy Market Summary

慢性炎症性脱髓鞘性多发性神经病市场概要

The total chronic inflammatory demyelinating polyneuropathy treatment market size is expected to grow positively by 2036 in the leading markets.

到2036年，主要市场的慢性炎性脱髓鞘性多发性神经病治疗市场总规模预计将实现正增长。

The United States accounted for the largest chronic inflammatory demyelinating polyneuropathy treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

与欧盟四国（德国、法国、意大利和西班牙）、英国和日本等其他主要市场相比，美国在2025年占据了最大的慢性炎性脱髓鞘性多发性神经病治疗市场规模。

The prevalence of CIDP is estimated to be around

慢性炎性脱髓鞘性多发性神经病（CIDP）的患病率估计约为

5-7 cases per 100,000

每10万人中有5-7例

individuals in the UK.

英国的个人。

Leading chronic inflammatory demyelinating polyneuropathy companies, such as

在慢性炎症性脱髓鞘性多发性神经病领域处于领先地位的公司，例如

Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, Takeda,

赛诺菲、Immunovant、argenx、Nuvig Therapeutics、Dianthus Therapeutics、武田制药，

and others, are developing new chronic inflammatory demyelinating polyneuropathy treatment drugs that can be available in the chronic inflammatory demyelinating polyneuropathy market in the coming years.

以及其他公司正在开发新的慢性炎性脱髓鞘性多发性神经病治疗药物，这些药物有望在未来几年内上市。

The promising chronic inflammatory demyelinating polyneuropathy therapies in clinical trials include

临床试验中颇具前景的慢性炎性脱髓鞘性多发性神经病疗法包括

Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, TAK-411,

Riliprubart、Batoclimab、Empasiprubart、NVG-2089、DNTH103、TAK-881、TAK-411

and others.

以及其他。

Discover how big is the chronic inflammatory demyelinating polyneuropathy market @

了解慢性炎性脱髓鞘性多发性神经病市场的规模 @

https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

Key Factors Driving the Growth of the Chronic Inflammatory Demyelinating Polyneuropathy Market

推动慢性炎性脱髓鞘性多发性神经病市场增长的关键因素

Rising Prevalence and Improved Diagnosis of CIDP:

慢性炎性脱髓鞘性多发性神经病（CIDP）患病率上升与诊断水平提高：

Increasing awareness among neurologists and healthcare professionals has led to earlier and more accurate diagnosis of CIDP. Advancements in diagnostic techniques, including electrophysiological testing, imaging technologies, and biomarker research, are improving disease identification, thereby expanding the treatable patient population..

神经科医生和医疗保健专业人员对慢性炎性脱髓鞘性多发性神经病（CIDP）的认知不断提高，促成了更早且更准确的诊断。包括电生理检查、影像技术和生物标志物研究在内的诊断技术的进步，正在改善疾病识别能力，从而扩大了可治疗的患者群体。

Growing Demand for Advanced Therapies:

对先进疗法的需求日益增长：

The market is witnessing increased demand for targeted and long-acting therapies that offer improved efficacy, reduced relapse rates, and enhanced patient convenience. Novel immunotherapies, subcutaneous immunoglobulin (SCIG) formulations, FcRn inhibitors, monoclonal antibodies, and complement-targeted therapies are gaining attention as alternatives to traditional intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange..

市场正见证对靶向且长效疗法的需求增长，这些疗法具有疗效更佳、复发率更低以及患者便利性更高的特点。新型免疫疗法、皮下注射免疫球蛋白（SCIG）制剂、FcRn抑制剂、单克隆抗体以及补体靶向疗法作为传统静脉注射免疫球蛋白（IVIG）、皮质类固醇和血浆置换的替代方案，正日益受到关注。

Increasing Adoption of Immunoglobulin Therapies:

免疫球蛋白疗法的应用日益广泛：

Immunoglobulin therapies remain the standard of care for CIDP treatment, and their continued adoption is contributing substantially to market growth. The availability of both intravenous and subcutaneous formulations has improved treatment accessibility and patient compliance.

免疫球蛋白疗法仍然是慢性炎性脱髓鞘性多发性神经病（CIDP）治疗的标准方案，其持续应用正显著推动市场增长。静脉注射和皮下注射两种剂型的可及性提高了治疗的可获得性和患者依从性。

Expanding Research and Development Activities:

扩大研发活动：

Pharmaceutical and biotechnology companies are significantly investing in research and development to introduce innovative therapies for CIDP. The growing clinical pipeline of therapies such as

制药和生物技术公司正在大力投资研发，以推出针对慢性炎性脱髓鞘性多发性神经病（CIDP）的创新疗法。不断增长的临床管线中的疗法，例如

Riliprubart

瑞利普鲁巴特

(Sanofi),

（赛诺菲）

Batoclimab

巴托利单抗

(Immunovant),

（Immunovant）

Empasiprubart

恩帕西普鲁巴特

(argenx),

（argenx）

NVG-2089

(Nuvig Therapeutics),

DNTH103

(Dianthus Therapeutics),

（Dianthus Therapeutics）

TAK-881 and TAK-411

TAK-881 和 TAK-411

(Takeda), and others, along with increased regulatory support for rare neurological disorders, is expected to accelerate market expansion over the coming years.

（武田药品工业公司）及其他企业，加之针对罕见神经系统疾病的监管支持力度加大，预计将在未来几年加速市场扩张。

Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the CIDP treatment still faces challenges, as many current therapies have safety concerns and a slow onset of action. Older medication classes often come with troublesome side effects, highlighting the need for safer and more effective options.

DelveInsight 的高级预测顾问 Ramandeep Singh 表示，慢性炎性脱髓鞘性多发性神经病（CIDP）的治疗仍面临挑战，因为许多现有疗法存在安全性问题且起效缓慢。较老的药物类别往往伴随令人困扰的副作用，这凸显了对更安全、更有效治疗方案的需求。

Encouragingly, new therapies in development offer hope for significant advancements in managing CIDP..

令人鼓舞的是，正在研发的新疗法为慢性炎性脱髓鞘性多发性神经病（CIDP）的管理带来重大进展的希望。

Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

慢性炎症性脱髓鞘性多发性神经病市场分析

The primary objective of treatment in CIDP is to suppress immune-mediated demyelination, prevent irreversible axonal damage, restore motor and sensory function, and maintain long-term disease remission while minimizing therapy-associated adverse effects.

慢性炎性脱髓鞘性多发性神经病（CIDP）治疗的主要目标是抑制免疫介导的脱髓鞘作用，防止不可逆的轴突损伤，恢复运动和感觉功能，并在尽量减少与治疗相关的不良反应的同时维持长期的疾病缓解。

As CIDP is a chronic autoimmune neuropathy characterized by relapsing or progressive peripheral nerve injury, treatment strategies primarily focus on modulating the dysregulated immune response underlying nerve damage.

由于慢性炎性脱髓鞘性多发性神经病（CIDP）是一种以复发性或进展性周围神经损伤为特征的慢性自身免疫性神经病，治疗策略主要集中在调节导致神经损伤的失调免疫反应。

Standard first-line treatment options include c

标准的一线治疗方案包括 c

orticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange (PLEX)

皮质类固醇、静脉注射免疫球蛋白（IVIg）和血浆置换（PLEX）

, each acting through distinct immunomodulatory mechanisms.

，各自通过不同的免疫调节机制发挥作用。

Corticosteroids, including prednisone and dexamethasone, help reduce inflammatory activity and are generally initiated at higher doses followed by gradual tapering once clinical improvement or disease stabilization is achieved.

皮质类固醇（包括泼尼松和地塞米松）有助于减轻炎症活动，通常以较高剂量起始，待临床症状改善或病情稳定后逐渐减量。

Subcutaneous immunoglobulin (SCIg)

皮下注射免疫球蛋白（SCIg）

has increasingly become an important maintenance therapy option due to its ability to provide stable immunoglobulin levels, enable home-based administration, and improve patient convenience and quality of life.

由于其能够提供稳定的免疫球蛋白水平、实现居家给药，并提高患者的便利性和生活质量，已日益成为重要的维持治疗选择。

Currently approved therapies include SCIg products such as

目前批准的疗法包括皮下注射免疫球蛋白（SCIg）产品，例如

HYQVIA

海雅维亚

and FcRn inhibitors such as

以及FcRn抑制剂，例如

VYVGART Hytrulo

, which are indicated for maintenance treatment or relapse prevention in adults with CIDP.

，适用于成人慢性炎性脱髓鞘性多发性神经病（CIDP）的维持治疗或复发预防。

Plasma exchange, which removes circulating pathogenic autoantibodies and immune complexes, may induce rapid symptomatic improvement and is particularly beneficial in severe or treatment-refractory cases, although therapeutic benefits are often temporary.

血浆置换可清除循环中的致病性自身抗体和免疫复合物，能够促使症状迅速改善，在重症或难治性病例中尤为有益，尽管其疗效往往短暂。

Treatment selection is guided by disease severity, progression, and patient comorbidities. Patients with mild disease may benefit from supportive measures such as rehabilitation, physiotherapy, and lifestyle modifications, whereas moderate-to-severe CIDP generally requires immunomodulatory intervention. .

治疗选择需依据疾病严重程度、进展情况及患者合并症进行指导。轻症患者可从康复、物理治疗和生活方式调整等支持性措施中获益，而中重度慢性炎性脱髓鞘性多发性神经病（CIDP）通常需要免疫调节干预。

Additionally, several emerging therapies are advancing through clinical development, including

此外，包括

Riliprubart

瑞利普鲁巴特

from Sanofi,

来自赛诺菲，

Batoclimab

巴托利单抗

from Immunovant, and

来自 Immunovant，以及

Claseprubart (DNTH103)

克拉塞普鲁巴特 (DNTH103)

from Dianthus Therapeutics, all of which are being investigated for their potential to enhance disease control and reduce relapse frequency.

来自Dianthus Therapeutics，所有这些药物正在被研究其增强疾病控制和减少复发频率的潜力。

Chronic Inflammatory Demyelinating Polyneuropathy Competitive Landscape

慢性炎症性脱髓鞘性多发性神经病竞争格局

Some of the CIDP drugs under development include

一些正在研发的慢性炎性脱髓鞘性多发性神经病（CIDP）药物包括

Riliprubart

瑞利普鲁巴特

(Sanofi),

（赛诺菲）

Batoclimab

巴托利单抗

(Immunovant),

(免疫万特)

Empasiprubart

恩帕西普鲁巴特

(argenx),

（argenx），

NVG-2089

(Nuvig Therapeutics),

（Nuvig Therapeutics），

DNTH103

(Dianthus Therapeutics),

（Dianthus Therapeutics），

TAK-881 and TAK-411

TAK-881 和 TAK-411

(Takeda), and others.

（武田）等。

Sanofi's Riliprubart (SAR445088)

赛诺菲的Riliprubart（SAR445088）

is a potential first-in-class IgG4 humanized monoclonal antibody designed to selectively inhibit activated C1s within the classical complement pathway of the innate immune system. By targeting C1s, the therapy may suppress key inflammatory processes involved in demyelination and axonal injury in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

是一种潜在的首创类IgG4人源化单克隆抗体，旨在选择性抑制先天免疫系统经典补体通路中活化的C1s。通过靶向C1s，该疗法可能抑制慢性炎性脱髓鞘性多发性神经病（CIDP）中涉及脱髓鞘和轴突损伤的关键炎症过程。

The drug is administered via a convenient subcutaneous route and is currently undergoing Phase III clinical evaluation for the treatment of CIDP..

该药物通过便捷的皮下途径给药，目前正处于治疗慢性炎性脱髓鞘性多发性神经病（CIDP）的III期临床评估阶段。

Immunovant's Batoclimab

Immunovant公司的巴托昔单抗

is a human monoclonal antibody targeting the neonatal Fc receptor (FcRn), with potential immunomodulatory effects. It binds to FcRn at the IgG binding site, blocking the interaction between FcRn and immunoglobulin G (IgG). This inhibition prevents FcRn-mediated IgG recycling, promotes IgG degradation, and reduces IgG-driven inflammatory activity.

是一种靶向新生儿Fc受体（FcRn）的人源单克隆抗体，具有潜在的免疫调节作用。它在IgG结合位点与FcRn结合，阻断FcRn与免疫球蛋白G（IgG）之间的相互作用。这种抑制作用可阻止FcRn介导的IgG再循环，促进IgG降解，并减少由IgG驱动的炎症活性。

Since IgG plays a central role in several autoimmune disorders, including CIDP, batoclimab may help mitigate disease-associated inflammation..

由于IgG在包括慢性炎性脱髓鞘性多发性神经病（CIDP）在内的多种自身免疫性疾病中发挥核心作用，巴托利单抗可能有助于减轻与疾病相关的炎症。

In March 2025, Immunovant announced topline results from its Phase IIb trial of batoclimab in CIDP, reporting clinically meaningful improvements in disability scores during the initial 12-week treatment period. Notably, patients who achieved greater reductions in IgG levels demonstrated higher response rates..

2025年3月，Immunovant公布了其batoclimab治疗慢性炎性脱髓鞘性多发性神经病（CIDP）的IIb期临床试验的顶线结果，报告称在最初的12周治疗期间，患者的残疾评分取得了具有临床意义的改善。值得注意的是，IgG水平降低幅度更大的患者表现出更高的应答率。

The anticipated launch of these emerging therapies are poised to transform the chronic inflammatory demyelinating polyneuropathy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic inflammatory demyelinating polyneuropathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期上市将在未来几年内改变慢性炎性脱髓鞘性多发性神经病（CIDP）的市场格局。随着这些前沿疗法不断成熟并获得监管批准，预计它们将重塑CIDP市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。

Discover more about what drugs are in development for CIDP @

了解更多关于正在研发中的慢性炎性脱髓鞘性多发性神经病（CIDP）药物 @

Chronic Inflammatory Demyelinating Polyneuropathy Drugs

慢性炎症性脱髓鞘性多发性神经病药物

Recent Developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market

慢性炎症性脱髓鞘性多发性神经病市场的最新进展

在

April 2026, argenx

2026年4月，argenx

presented data on VYVGART (IV and SC/Hytrulo formulations) along with pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology Annual Meeting.

在2026年美国神经病学学会年会上，展示了VYVGART（静脉注射和皮下注射/Hytrulo制剂）以及管线候选药物empasiprubart和adimanebart的数据。

在

March 2026, Dianthus Therapeutics

2026年3月，Dianthus Therapeutics

announced an early GO decision following an interim responder analysis in the Phase 3 CAPTIVATE trial evaluating claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

在评估claseprubart治疗慢性炎性脱髓鞘性多发性神经病（CIDP）的III期CAPTIVATE试验中，基于中期应答者分析结果，宣布提前做出GO决策。

在

June 2025, Sanofi

2025年6月，赛诺菲

reported that the Ministry of Health, Labour and Welfare (MHLW) in Japan granted orphan drug designation (ODD) to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for people with CIDP.

据报道，日本厚生劳动省（MHLW）授予riliprubart孤儿药资格认定（ODD）。Riliprubart是一种单克隆抗体，可选择性抑制经典补体通路中的活化C1s，用于治疗慢性炎性脱髓鞘性多发性神经病（CIDP）患者。

What is Chronic Inflammatory Demyelinating Polyneuropathy?

什么是慢性炎性脱髓鞘性多发性神经病？

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune neurological disorder in which the body's immune system mistakenly attacks the myelin sheath, the protective covering surrounding peripheral nerves. This damage disrupts nerve signal transmission, leading to progressive weakness, impaired motor function, sensory loss, numbness, tingling, and reduced reflexes, typically affecting the arms and legs.

慢性炎性脱髓鞘性多发性神经病（CIDP）是一种罕见的自身免疫性神经系统疾病，患者的免疫系统会错误地攻击周围神经的保护层——髓鞘。这种损伤会干扰神经信号的传导，导致进行性肌无力、运动功能受损、感觉丧失、麻木、刺痛以及反射减弱，通常累及四肢。

CIDP can develop gradually over weeks to months and may follow either a relapsing-remitting or steadily progressive course. Although the exact cause remains unclear, early diagnosis and treatment with therapies such as corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange can help manage symptoms, improve nerve function, and prevent long-term disability..

慢性炎性脱髓鞘性多发性神经病（CIDP）可在数周至数月内逐渐发展，病程可呈复发-缓解型或持续进展型。尽管其确切病因尚不明确，但早期诊断并结合皮质类固醇、静脉注射免疫球蛋白（IVIg）或血浆交换等治疗手段，有助于控制症状、改善神经功能并预防长期残疾。

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

慢性炎症性脱髓鞘性多发性神经病流行病学细分

The chronic inflammatory demyelinating polyneuropathy epidemiology section provides insights into the historical and current chronic inflammatory demyelinating polyneuropathy patient pool and forecasted trends for the leading markets. Epidemiologic rates of CIDP are higher among males vs. females aged ≥55 years, distinguishing CIDP from other autoimmune diseases, which are typically more prevalent in women across the lifespan..

慢性炎症性脱髓鞘性多发性神经病流行病学章节提供了关于主要市场历史及当前慢性炎症性脱髓鞘性多发性神经病患者群体规模和预测趋势的见解。在55岁及以上人群中，男性的CIDP流行病学率高于女性，这一特点使CIDP区别于其他通常在整个生命周期中女性患病率更高的自身免疫性疾病。

The chronic inflammatory demyelinating polyneuropathy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

慢性炎性脱髓鞘性多发性神经病治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：

Total Prevalent Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）的总患病病例数

Total Diagnosed Prevalent Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）的确诊总患病病例数

Gender-specific Diagnosed Prevalent Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）按性别分列的确诊患病病例

Subtype-specific Diagnosed Prevalent Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）各亚型的确诊患病病例

Comorbidity-specific Diagnosed Prevalent Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）按合并症划分的诊断现患病例数

Total Treated Cases of CIDP

慢性炎性脱髓鞘性多发性神经病（CIDP）治疗病例总数

Chronic Inflammatory Demyelinating Polyneuropathy Market Report Metrics

慢性炎性脱髓鞘性多发性神经病市场报告指标

Details

详情

Study Period

学习周期

2022–2036

Coverage

覆盖范围

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

7国集团[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation

慢性炎性脱髓鞘性多发性神经病流行病学细分

Total Prevalent Cases of CIDP, Total Diagnosed Prevalent Cases of CIDP, Gender-specific Diagnosed Prevalent Cases of CIDP, Subtype-specific Diagnosed Prevalent Cases of CIDP, Comorbidity-specific Diagnosed Prevalent Cases of CIDP, and Total Treated Cases of CIDP

CIDP总患病病例数、CIDP已诊断总患病病例数、CIDP按性别分列的已诊断患病病例数、CIDP按亚型分列的已诊断患病病例数、CIDP按合并症分列的已诊断患病病例数，以及CIDP总治疗病例数

Key Chronic Inflammatory Demyelinating Polyneuropathy Companies

慢性炎性脱髓鞘性多发性神经病领域的关键企业

Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, Takeda, and others

赛诺菲、Immunovant、argenx、Nuvig Therapeutics、Dianthus Therapeutics、武田制药等

Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies

慢性炎性脱髓鞘性多发性神经病的关键疗法

Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, TAK-411, HYQVIA, VYVGART Hytrulo, and others

Riliprubart、Batoclimab、Empasiprubart、NVG-2089、DNTH103、TAK-881、TAK-411、HYQVIA、VYVGART Hytrulo 等

Scope of the

范围

Chronic Inflammatory Demyelinating Polyneuropathy

慢性炎性脱髓鞘性多发性神经病

Market Report

市场报告

Chronic Inflammatory Demyelinating Polyneuropathy Patient Population Forecast

慢性炎症性脱髓鞘性多发性神经病患者人群预测

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size

慢性炎症性脱髓鞘性多发性神经病治疗药物市场规模

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis

慢性炎性脱髓鞘性多发性神经病在研管线分析

Chronic Inflammatory Demyelinating Polyneuropathy Market Size and Trends

慢性炎性脱髓鞘性多发性神经病市场规模与趋势

Chronic Inflammatory Demyelinating Polyneuropathy Market Opportunity

慢性炎症性脱髓鞘性多发性神经病市场机遇

Chronic Inflammatory Demyelinating Polyneuropathy Market Unmet Needs

慢性炎性脱髓鞘性多发性神经病市场的未满足需求

KOL's Views on Chronic Inflammatory Demyelinating Polyneuropathy

关键意见领袖对慢性炎性脱髓鞘性多发性神经病的观点

Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

慢性炎性脱髓鞘性多发性神经病市场准入与报销

Download the report to understand what drugs are in development for CIDP @

下载报告以了解慢性炎性脱髓鞘性多发性神经病（CIDP）在研药物

Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis

慢性炎症性脱髓鞘性多发性神经病市场分析

Table of Contents

Chronic Inflammatory Demyelinating Polyneuropathy Market Key Insights

慢性炎症性脱髓鞘性多发性神经病市场关键洞察

Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction

慢性炎症性脱髓鞘性多发性神经病市场报告简介

CIDP Market Overview at a Glance

慢性炎性脱髓鞘性多发性神经病（CIDP）市场概览

3.1

Market Share (%) Distribution of CIDP by Therapies in 2022 in the 7MM

2022年七大主要市场（7MM）按疗法划分的慢性炎性脱髓鞘性多发性神经病（CIDP）市场份额（%）分布

3.2

Market Share (%) Distribution of CIDP by Therapies in 2036 in the 7MM

2036年七国市场（7MM）中慢性炎性脱髓鞘性多发性神经病（CIDP）按治疗方案划分的市场份额（%）分布

Methodology of Epidemiology and Market

流行病学与市场方法论

Executive Summary

执行摘要

Key Events

关键事件

Disease Background and Overview

疾病背景与概述

7.1

Introduction

简介

7.2

Signs and Symptoms

体征与症状

7.3

Causes

原因

7.4

Related Conditions